• WY-14643: Selective PPARα Agonist for Metabolic and Tumor...

  2025-10-02

  WY-14643 (Pirinixic Acid) uniquely combines potent PPARα selectivity with dual PPARα/γ activity, enabling advanced research in metabolic regulation and tumor microenvironment modulation. Its robust anti-inflammatory and insulin-sensitizing properties make it an indispensable tool for dissecting PPAR signaling in both metabolic disorders and cancer.

• Paclitaxel (Taxol): Redefining Personalized Cancer Resear...

  2025-10-01

  Explore how Paclitaxel (Taxol), a leading microtubule polymer stabilizer, is transforming personalized cancer research by enabling advanced tumor microenvironment modeling and drug resistance studies. Discover unique scientific applications beyond standard reviews.

• Diclofenac and the Future of Translational Inflammation R...

  2025-09-30

  This thought-leadership article explores the transformative role of Diclofenac, a non-selective COX inhibitor, in translational inflammation and pain signaling research. By integrating mechanistic insights, cutting-edge human iPSC-derived intestinal organoid models, and strategic experimental approaches, it offers a roadmap for researchers aiming to bridge classic pharmacology and modern in vitro systems. The article contextualizes Diclofenac's utility beyond traditional COX inhibition assays, referencing pivotal studies and highlighting best practices for translational researchers.

• WY-14643 (Pirinixic Acid): Precision Modulation of PPARα ...

  2025-09-29

  Discover how WY-14643, a selective PPARα agonist, uniquely modulates lipid metabolism and inflammation in both metabolic disorders and the tumor microenvironment. This in-depth analysis explores advanced mechanisms, translational research, and the latest insights beyond conventional approaches.

• Paclitaxel (Taxol): Precision Modulation of Microtubule D...

  2025-09-28

  Explore the multifaceted role of Paclitaxel as a microtubule polymer stabilizer in cancer research and peripheral neuropathy models. This article uniquely delves into mechanistic depth, translational applications, and the integration of emerging mRNA therapeutics, offering insights beyond standard reviews.

• WY-14643 (Pirinixic Acid): Precision PPARα/γ Modulation f...

  2025-09-27

  Explore the multifaceted impact of WY-14643, a selective PPARα agonist, on metabolic disorder research and tumor microenvironment modulation. This article delivers unique mechanistic insights and translational perspectives, extending beyond existing reviews.

• WY-14643 (Pirinixic Acid): A Molecular Tool for Dissectin...

  2025-09-26

  Explore the multifaceted role of WY-14643, a selective PPARα agonist, in unraveling the molecular links between lipid metabolism, inflammation, and tumor progression. This article uniquely integrates recent multiomics evidence, positioning WY-14643 as a pivotal agent for advanced metabolic disorder and oncology research.

• WY-14643 (Pirinixic Acid): Advanced PPARα Modulation for ...

  2025-09-25

  Explore how WY-14643 (Pirinixic Acid), a potent PPARα agonist, drives next-generation research in metabolic disorders and tumor microenvironments. This article delivers novel insights into dual PPARα/γ modulation, insulin sensitivity enhancement, and the mechanistic interplay with TNF-α mediated inflammation.

• VX-765: Unraveling Caspase-1 Inhibition Beyond Pyroptosis

  2025-09-24

  Explore the advanced mechanisms of VX-765, a selective caspase-1 inhibitor, in dissecting cell death pathways and inflammatory cytokine modulation. This article uniquely integrates RNA Pol II signaling insights, offering a fresh perspective on inflammation research.

• Verapamil HCl: Beyond Calcium Blockade—Emerging Roles in ...

  2025-09-23

  Verapamil HCl, a phenylalkylamine L-type calcium channel blocker, is gaining attention for its multifaceted roles in research, including apoptosis induction in myeloma cells and inflammation attenuation in arthritis models. This article explores novel molecular insights and translational applications, positioning Verapamil HCl at the interface of calcium signaling, apoptosis, and bone biology.

• Pioglitazone as a PPARγ Agonist: Novel Mechanistic Insigh...

  2025-09-22

  Explore the multifaceted utility of pioglitazone, a potent PPARγ agonist, in dissecting insulin resistance mechanisms and inflammator

• WY-14643 (Pirinixic Acid): Advancing Metabolic Disorder R...

  2025-09-19

  Explore the multifaceted applications of WY-14643 (Pirinixic Acid), a selective PPARα agonist, in metabolic disorder research and tumor microenvironment studies. This article examines mechanistic insights, recent findings, and practical considerations for using WY-14643 in scientific investigations.

• VX-765: Advancing Caspase-1 Inhibition in Inflammation an...

  2025-09-18

  Explore the scientific advances enabled by VX-765, a selective oral caspase-1 inhibitor, in dissecting inflammatory signaling and pyroptosis. This article details VX-765's utility in modulating IL-1β and IL-18 release, its applications in disease models, and its role in mechanistic cell death studies.

• Last decade has provided a number

  2025-03-03

  

  Last decade has provided a number of studies indicating that AhR signaling could play a role both in the development and in progression of multiple cancer types, with potential implications for cancer therapy (for review see (Kolluri et al., 2017; Murray et al., 2014)). Activation of AhR is consider

• Adiponectin also suppresses inflammatory stimuli induced NF

  2025-03-03

  

  Adiponectin also suppresses inflammatory stimuli-induced NF-kappaB activation, which may significantly contribute to the anti-diabetic and anti-atherogenic effects of adiponectin (Ouchi et al., 2000). The downstream mediators of AdipoR1 and AdipoR2, RPPAR and AMPK increase inflammatory responses by

15101 records 1/1007 page Next 12345 下5页 Last page